Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.

Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS.

Am J Psychiatry. 2006 Feb;163(2):210-6.

PMID:
16449473
2.

Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.

Solmi M, Veronese N, Zaninotto L, van der Loos ML, Gao K, Schaffer A, Reis C, Normann C, Anghelescu IG, Correll CU.

CNS Spectr. 2016 Oct;21(5):403-418.

PMID:
27686028
3.

Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.

van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, Nolen WA; LamLit Study Group.

J Clin Psychiatry. 2009 Feb;70(2):223-31. Epub 2008 Dec 30.

PMID:
19200421
4.

A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression.

McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, Ascher J.

J Clin Psychiatry. 2004 Feb;65(2):204-10.

PMID:
15003074
5.

Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).

Vieta E, Herraiz M, Fernández A, Gastó C, Benabarre A, Colom F, Martínez-Arán A, Reinares M.

J Clin Psychiatry. 2001 Aug;62(8):623-30.

PMID:
11561935
7.

Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.

Ivković M, Damjanović A, Jovanović A, Cvetić T, Jasović-Gasić M.

Psychiatr Danub. 2009 Jun;21(2):187-93.

8.

Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Parikh SV, LeBlanc SR, Ovanessian MM.

Can J Psychiatry. 2010 Mar;55(3):136-43.

PMID:
20370963
9.
10.

A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.

Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, Thompson PM, Shelton RC.

J Clin Psychiatry. 2011 Oct;72(10):1405-12. doi: 10.4088/JCP.09m05355gre.

PMID:
21367355
11.

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD.

J Clin Psychiatry. 1999 Feb;60(2):79-88.

PMID:
10084633
12.

Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament.

Manning JS, Haykal RF, Connor PD, Cunningham PD, Jackson WC, Long S.

J Affect Disord. 2005 Feb;84(2-3):259-66.

PMID:
15708424
13.

Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety.

Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME, Filkowski MM, Hennen J, Sachs GS, Goodwin FK, Baldessarini RJ.

J Clin Psychiatry. 2010 Apr;71(4):372-80. doi: 10.4088/JCP.08m04909gre.

PMID:
20409444
14.

The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial.

Ketter TA, Greist JH, Graham JA, Roberts JN, Thompson TR, Nanry KP.

J Clin Psychiatry. 2006 Mar;67(3):400-6.

PMID:
16649826
15.

Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder.

Bowden CL, Myers JE, Grossman F, Xie Y.

J Clin Psychiatry. 2004 May;65(5):707-14.

PMID:
15163260
16.

Early Improvement of Specific Symptoms Predicts Subsequent Recovery in Bipolar Depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Data.

Mizushima J, Uchida H, Tada M, Suzuki T, Mimura M, Nio S.

J Clin Psychiatry. 2017 Feb;78(2):e146-e151. doi: 10.4088/JCP.15m10573.

PMID:
28234437
17.

Effectiveness of lamotrigine in bipolar disorder in a clinical setting.

Ketter TA, Brooks JO, Hoblyn JC, Champion LM, Nam JY, Culver JL, Marsh WK, Bonner JC.

J Psychiatr Res. 2008 Nov;43(1):13-23. doi: 10.1016/j.jpsychires.2008.02.007.

PMID:
18423667
18.

Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review.

Sharma V, Khan M, Corpse C.

J Affect Disord. 2008 Nov;111(1):100-5. doi: 10.1016/j.jad.2008.01.029. Epub 2008 Mar 7.

PMID:
18314200
19.

Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers.

Chang JS, Moon E, Cha B, Ha K.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1322-6. doi: 10.1016/j.pnpbp.2010.07.020. Epub 2010 Jul 29.

PMID:
20673782
20.

Risperidone and paroxetine given singly and in combination for bipolar depression.

Shelton RC, Stahl SM.

J Clin Psychiatry. 2004 Dec;65(12):1715-9.

PMID:
15641878

Supplemental Content

Support Center